Perspectives of Canadian Health Care Providers on Fetal Alcohol Spectrum Disorder: Has Anything Changed in 15 years? A Brief Report

2021 ◽  
Author(s):  
Courtney R. Green ◽  
Kyla J. Kaminsky ◽  
Suzanne Tough ◽  
Nicole Roberts ◽  
Taniya S. Nagpal ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Providers ◽  
Fetal Alcohol Spectrum Disorder ◽  
Spectrum Disorder ◽  
Care Providers ◽  
Fetal Alcohol ◽  
Canadian Health ◽  
Canadian Health Care ◽  
Fetal Alcohol Spectrum

scholarly journals Perceptions of Fetal Alcohol Spectrum Disorder (FASD) at a Mental Health Outpatient Treatment Provider in Minnesota

2018 ◽  
Vol 16 (1) ◽  
pp. 16 ◽  
Author(s):  
Jerrod Brown ◽  
Diane Harr
Keyword(s):  
Mental Health ◽  
Health Care Providers ◽  
Outpatient Treatment ◽  
Fetal Alcohol Spectrum Disorder ◽  
Spectrum Disorder ◽  
Care Providers ◽  
Fetal Alcohol ◽  
Basic Symptoms ◽  
Impact On Treatment ◽  
Fetal Alcohol Spectrum

Resulting from prenatal exposure to alcohol, Fetal Alcohol Spectrum Disorder (FASD) is characterized by deficits in adaptive and cognitive functioning. This disorder is typically accompanied by co-occurring disorders and conditions (e.g., mood, anxiety, psychosis, and substance use disorders). This complicated presentation of diverse symptoms makes the process of screening, assessing, and diagnosing FASD very difficult, limiting the likelihood that clients receive the treatment and services that they need. Although mental health care providers have an opportunity to intervene on behalf of clients with FASD, professionals may not be very familiar or comfortable with this complicated and life-altering disorder. The present study explores the familiarity of 79 mental health outpatient treatment professionals’ personal knowledge and training about FASD. Findings suggest that the majority of respondents had received at least some FASD training, understood the basic symptoms of FASD, and were realistic about FASD’s impact on treatment.

scholarly journals Fetal Alcohol Spectrum Disorder: What does Public Awareness Tell Us about Prevention Programming?

2019 ◽  
Vol 16 (21) ◽  
pp. 4229
Author(s):  
Peter Choate ◽  
Dorothy Badry ◽  
Bruce MacLaurin ◽  
Kehinde Ariyo ◽  
Dorsa Sobhani
Keyword(s):  
Health Care Providers ◽  
Fetal Alcohol Spectrum Disorder ◽  
Public Awareness ◽  
Secondary Data ◽  
Spectrum Disorder ◽  
Health Concern ◽  
Care Providers ◽  
Childbearing Age ◽  
Fetal Alcohol ◽  
Fetal Alcohol Spectrum

The prevalence of Fetal Alcohol Spectrum Disorder (FASD) does not appear to be diminishing over time. Indeed, recent data suggests that the disorder may be more prevalent than previously thought. A variety of public education programs developed over the last 20 years have promoted alcohol abstention during pregnancy, yet FASD remains a serious public health concern. This paper reports on a secondary data analysis of public awareness in one Canadian province looking at possible creative pathways to consider for future prevention efforts. The data indicates that the focus on women of childbearing age continues to make sense. The data also suggests that targeting formal (health care providers for examples) and informal support (partner, spouse, family, and friends) might also be valuable. They are seen as sources of encouragement, so ensuring they understand the risks, as well as effective ways to encourage abstinence or harm reduction, may be beneficial for both the woman and the pregnancy. Educating people who might support a woman in pregnancy may be as important as programs targeted towards women who may become or are pregnant. The data also suggests that there is already a significant level of awareness of FASD, thus highlighting the need to explore the effectiveness and value of current prevention approaches.

Intrauterine Contraception: Knowledge and Prescribing Practices of Canadian Health Care Providers

2019 ◽  
Vol 41 (8) ◽  
pp. 1084-1092 ◽  
Author(s):  
Jocelynn Cook ◽  
Ashley Waddington ◽  
Denise Black ◽  
Dustin Costescu ◽  
Danica Desjardins ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Providers ◽  
Care Providers ◽  
Prescribing Practices ◽  
Intrauterine Contraception ◽  
Canadian Health ◽  
Canadian Health Care

scholarly journals Canadian recommendations for the management of breakthrough cancer pain

2016 ◽  
Vol 23 (2) ◽  
pp. 96 ◽  
Author(s):  
P. Daeninck ◽  
B. Gagnon ◽  
R. Gallagher ◽  
J.D. Henderson ◽  
Y. Shir ◽  
...  
Keyword(s):  
Health Care ◽  
Cancer Pain ◽  
Health Care Providers ◽  
Immediate Release ◽  
Care Providers ◽  
Onset Of Action ◽  
Breakthrough Cancer Pain ◽  
Appropriate Treatment ◽  
Canadian Health ◽  
Canadian Health Care

Breakthrough cancer pain (btcp) represents an important element in the spectrum of cancer pain management. Because most btcp episodes peak in intensity within a few minutes, speed of medication onset is crucial for proper control. In Canada, several current provincial guidelines for the management of cancer pain include a brief discussion about the treatment of btcp; however, there are no uniform national recommendations for the management of btcp. That lack, accompanied by unequal access to pain medication across the country, contributes to both regional and provincial variability in the management of btcp.Currently, immediate-release oral opioids are the treatment of choice for btcp. This approach might not always offer optimal speed for onset of action and duration to match the rapid nature of an episode of btcp. Novel transmucosal fentanyl formulations might be more appropriate for some types of btcp, but limited access to such drugs hinders their use. In addition, the recognition of btcp and its proper assessment, which are crucial steps toward appropriate treatment selection, remain challenging for many health care professionals.To facilitate appropriate management of btcp, a group of prominent Canadian specialists in palliative care, oncology, and anesthesiology convened to develop a set of recommendations and suggestions to assist Canadian health care providers in the treatment of btcp and the alleviation of the suffering and discomfort experienced by adult cancer patients.

scholarly journals Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV-Infected Adults

2010 ◽  
Vol 21 (4) ◽  
pp. 159-172 ◽  
Author(s):  
Anita Rachlis ◽  
Marianne Harris ◽  
Richard Lalonde ◽  
Stephen D Shafran ◽  
Cécile Tremblay ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Providers ◽  
Hiv Treatment ◽  
Care Providers ◽  
Expert Opinions ◽  
Hiv Management ◽  
Conference Presentations ◽  
Canadian Health ◽  
Canadian Health Care ◽  
Group Members

BACKGROUND AND OBJECTIVES: A Canadian group, consisting of six physicians and an HIV researcher with significant experience and knowledge in HIV management, reviewed the available data and developed guidelines for Canadian health care providers (who treat HIV infection) on the appropriate use of maraviroc (UK-427,857) in HIV-infected adults.METHODS: Evidence from the published literature and conference presentations, as well as the expert opinions of the group members were considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from four other physicians across Canada with expertise in HIV treatment and experience with the use of maraviroc. The final recommendations represent the core group’s consensus agreement once all feedback was considered.RESULTS/CONCLUSIONS: Recommendations were developed to guide physicians and other health care providers in the optimal use of maraviroc. The recommendations were considered in light of the fact that the decision to include maraviroc in an antiretroviral regimen depends not only on issues that concern all antiretroviral agents, such as efficacy, safety, resistance and drug interactions, but also on the issue of viral tropism, which is unique to maraviroc and other CCR5 inhibitors.

Sign in / Sign up

Export Citation Format

Share Document